$0.66
1.59% today
Nasdaq, Apr 01, 06:45 pm CET
ISIN
US04962H5063
Symbol
ATOS

Atossa Genetics Inc. Stock price

$0.67
-0.09 12.12% 1M
-0.85 55.73% 6M
-0.27 28.73% YTD
-1.33 66.36% 1Y
-0.58 46.17% 3Y
-0.66 49.41% 5Y
-323.33 99.79% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.02 3.35%
ISIN
US04962H5063
Symbol
ATOS
Sector

Key metrics

Market capitalization $86.92m
Enterprise Value $15.73m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.22
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-27.62m
Free Cash Flow (TTM) Free Cash Flow $-21.05m
Cash position $71.19m
EPS (TTM) EPS $-0.20
P/E forward negative
Short interest 6.82%
Show more

Is Atossa Genetics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Atossa Genetics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Atossa Genetics Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Atossa Genetics Inc. forecast:

Buy
100%

Financial data from Atossa Genetics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.02 0.02
0% 0%
-
-0.02 -0.02
0% 0%
-
- Selling and Administrative Expenses 13 13
4% 4%
-
- Research and Development Expense 14 14
19% 19%
-
-28 -28
12% 12%
-
- Depreciation and Amortization 0.02 0.02
0% 0%
-
EBIT (Operating Income) EBIT -28 -28
12% 12%
-
Net Profit -26 -26
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Atossa Genetics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Atossa Genetics Inc. Stock News

Neutral
Seeking Alpha
7 days ago
Atossa Therapeutics, Inc. (NASDAQ:ATOS ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Michael Parks - VP of Investor and Public Relations Steven Quay - President and CEO Heather Rees - CFO Conference Call Participants Emily Bodnar - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good morning, everyone, and welcome to the Atossa Therapeutics Fourth Qu...
Neutral
GlobeNewsWire
7 days ago
Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its finan...
Neutral
GlobeNewsWire
12 days ago
Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time
More Atossa Genetics Inc. News

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Head office United States
CEO Steven Quay
Employees 15
Founded 2008
Website www.atossatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today